Morepen Laboratories Ltd
Morepen Laboratories Ltd Q4 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Morepen Laboratories Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY26 revenue: Rs. Q4 FY26 EBITDA: Rs.
From Morepen Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 revenue: Rs. 472 crore, up 22% year-on-year (YoY) from Rs. 385 crore in Q4 FY25 (Page 12, 5)
- API segment Q4 growth: 17% YoY (Page 5)
- Medical Devices segment Q4 growth: 31% YoY (Page 5)
- FY26 total revenue growth: 8% YoY, Rs. 597 crore reported (Page 10, 5)
- Gross revenue FY25: Rs. 1570 crore; FY26 forecast: Rs. 1703 crore, implying 8-9% growth (Page 13)
- Q4 FY26 EBITDA margin about 6.8%; FY26 EBITDA 10.8% (Page 12, 13)
- Outlook: Long-duration manufacturing programs started Q4 FY26 expected to progressively support operating leverage and growth (Pages 12, 13)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Manufacturing capacity expansion planned from existing ~500 KL production base to ~800 KL (mid-term) and ~1000 KL (long-term).
- Focus on long-duration supply programs to improve operating leverage and stable recurring revenues.
- CDMO & Manufacturing: Audits and validation batches completed; commercial production commenced; phased delivery schedule received, starting Q4 FY26.
- Building 20% ‘ready capacity’ to onboard new customers and developing speciality portfolio for select clients.
- No specific monetary amounts for capex cited in the slides provided.
- Status: Commercial supplies under long-duration manufacturing programs began in Q4 FY26.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation reports that Morepen Laboratories Limited has secured a multi-year mandate worth Rs. 823 crore under its commercial program milestones (Page 3).
- It mentions that commercial production has commenced and phased delivery is scheduled to start in the coming weeks (Page 3).
- On Page 13, it is stated that Q4 FY26 marked the commencement of commercial supplies under long-duration manufacturing programs, indicating progress in order fulfillment.
2 more points management made on order book & pipeline
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key investor presentation takeaways from Anuh Pharma Ltd's Q4 FY26 investor presentation — and how i
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY26 inv
- Remus Pharmaceuticals Ltd (Q4 FY26)
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key investor presentation takeaways from Remus Pharmaceuticals Ltd's Q4
- Lincoln Pharmaceuticals Ltd (Q4 FY26)
EBITDA: ₹26 crore, a 3% year-on-year increase . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how i
Frequently Asked Questions
What were Morepen Laboratories Ltd Q4 FY26 results?
Q4 FY26 revenue: Rs. Q4 FY26 EBITDA: Rs.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Manufacturing capacity expansion planned from existing ~500 KL production base to ~800 KL (mid-term) and ~1000 KL (long-term).
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.